Glioblastoma specimens with TP53 mutations do not show EGFRvIII amplification

被引：1

作者：

Ewelina, Stoczynska-Fidelus ^{[1
]}

Monika, Witusik-Perkowska ^{[1
]}

Mateusz, Banaszczyk ^{[1
]}

Michal, Bienkowski ^{[1
]}

Malgorzata, Szybka ^{[1
]}

Sylwester, Piaskowski ^{[1
]}

Magdalena, Cybula ^{[1
]}

Dariusz, Jaskolski ^{[2
]}

Wielistaw, Papierz ^{[3
]}

Pawel, Liberski Piotr ^{[1
]}

Piotr, Rieske ^{[1
]}

机构：

[1] Med Univ Lodz, Dept Mol Pathol & Neuropathol, Chair Oncol, PL-92216 Lodz, Poland

[2] Med Univ Lodz, Dept Neurosurg, PL-90153 Lodz, Poland

[3] Med Univ Lodz, Dept Pathomorphol, PL-92216 Lodz, Poland

来源：

CANCER GENETICS | 2011年 / 204卷 / 05期

关键词：

GROWTH-FACTOR-RECEPTOR; MULTIFORME;

D O I：

10.1016/j.cancergen.2011.03.005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：282 / 283

页数：2

共 10 条

[1] AMPLIFIED AND REARRANGED EPIDERMAL GROWTH-FACTOR RECEPTOR GENES IN HUMAN GLIOBLASTOMAS REVEAL DELETIONS OF SEQUENCES ENCODING PORTIONS OF THE N-TERMINAL AND OR C-TERMINAL TAILS [J].

EKSTRAND, AJ ;

SUGAWA, N ;

JAMES, CD ;

COLLINS, VP .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (10) :4309-4313

[2] Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients [J].

Heimberger, AB ;

Hlatky, R ;

Suki, D ;

Yang, D ;

Weinberg, J ;

Gilbert, M ;

Sawaya, R ;

Aldape, K .

CLINICAL CANCER RESEARCH, 2005, 11 (04) :1462-1466

[3] The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling [J].

Huang, HJS ;

Nagane, M ;

Klingbeil, CK ;

Lin, H ;

Nishikawa, R ;

Ji, XD ;

Huang, CM ;

Gill, GN ;

Wiley, HS ;

Cavenee, WK .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (05) :2927-2935

[4] The Epidermal Growth Factor Receptor as a Therapeutic Target in Glioblastoma Multiforme and other Malignant Neoplasms [J].

Loew, S. ;

Schmidt, U. ;

Unterberg, A. ;

Halatsch, M. -E. .

ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2009, 9 (06) :703-715

[5] Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors [J].

Mellinghoff, IK ;

Wang, MY ;

Vivanco, I ;

Haas-Kogan, DA ;

Zhu, SJ ;

Dia, EQ ;

Lu, KV ;

Yoshimoto, K ;

Huang, JHY ;

Chute, DJ ;

Riggs, BL ;

Horvath, S ;

Liau, LM ;

Cavenee, WK ;

Rao, PN ;

Beroukhim, R ;

Peck, TC ;

Lee, JC ;

Sellers, WR ;

Stokoe, D ;

Prados, M ;

Cloughesy, TF ;

Sawyers, CL ;

Mischel, PS .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (19) :2012-2024

[6] Genetic pathways to primary and secondary glioblastoma [J].

Ohgaki, Hiroko ;

Kleihues, Paul .

AMERICAN JOURNAL OF PATHOLOGY, 2007, 170 (05) :1445-1453

[7]

Okada Y, 2003, CANCER RES, V63, P413

[8]

Shinojima N, 2003, CANCER RES, V63, P6962

[9] Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas [J].

Watanabe, K ;

Sato, K ;

Yonekawa, Y ;

Kleihues, P ;

Ohgaki, H .

BRAIN PATHOLOGY, 1996, 6 (03) :217-223

[10] Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples [J].

Yoshimoto, Koji ;

Dang, Julie ;

Zhu, Shaojun ;

Nathanson, David ;

Huang, Tiffany ;

Dumont, Rebecca ;

Seligson, David B. ;

Yong, William H. ;

Xiong, Zhenggang ;

Rao, Nagesh ;

Winther, Henrik ;

Chakravarti, Arnab ;

Bigner, Darell D. ;

Mellinghoff, Ingo K. ;

Horvath, Steve ;

Cavenee, Webster K. ;

Cloughesy, Timothy F. ;

Mischel, Paul S. .

CLINICAL CANCER RESEARCH, 2008, 14 (02) :488-493

← 1 →